Itacitinib

Overview

Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients	2023/04/21	NCT05823571	Phase 1	Recruiting	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy	2023/03/07	NCT05757219	Phase 2	Recruiting	H. Lee Moffitt Cancer Center and Research Institute
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors	2022/12/21	NCT05660421	Phase 2	Withdrawn	Douglas Johnson
Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease	2022/09/30	NCT05561985	N/A	AVAILABLE	Incyte Corporation
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants	2022/05/06	NCT05364762	Phase 2	Active, not recruiting	City of Hope Medical Center
Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB	2021/09/30	NCT05063110	Phase 2	UNKNOWN	Assistance Publique - Hôpitaux de Paris
Itacitinib for the Prevention of Graft Versus Host Disease	2021/04/26	NCT04859946	Phase 1	Active, not recruiting	M.D. Anderson Cancer Center
Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis	2021/03/10	NCT04789850	Phase 2	Recruiting	Assistance Publique - Hôpitaux de Paris
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib	2020/11/23	NCT04640025	Phase 2	Active, not recruiting	Incyte Corporation
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)	2020/11/16	NCT04629508	Phase 2	Completed	Incyte Corporation

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Researchers Unveil New Strategies to Harness Tumor Microenvironment for Enhanced Cancer Immunotherapy

a month ago

Researchers at the 2025 ASCO Annual Meeting revealed how the tumor microenvironment's complex balance of pro-tumor and anti-tumor immune forces can be manipulated to improve immunotherapy responses.

Novel Drug Regimens Show Promise in Reducing Graft-versus-Host Disease After Stem Cell Transplants

7 months ago

A novel drug regimen (SIR/CSP/PTCy) significantly reduced moderate to severe chronic graft-versus-host disease (cGVHD) to 1% compared to 28% with the SIR/CSP/MMF regimen.

New Treatment Strategies Emerge for Managing CAR T-Cell Therapy Side Effects

10 months ago

CAR T-cell therapy commonly triggers cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), with incidence rates of 57-93% and 20-70% respectively.

Parkinson's Drug DNL-151 Phase III Trial Terminated; Lerodalcibep Shows Promise in Hypercholesterolemia

2 years ago

• Denali Therapeutics' DNL-151 Phase III trial for Parkinson's disease was terminated, leading to a 14-point decrease in its Likelihood of Approval (LoA). • LIB Therapeutics' lerodalcibep showed positive Phase III data in heterozygous familial hypercholesterolemia (HeFH), increasing its LoA by 11 points to 65%. • AstraZeneca's MEDI-7352 Phase IIb trial in osteoarthritis pain was completed, resulting in a six-point increase in its Phase Transition Success Rate (PTSR) to 45%. • Incyte's itacitinib saw its PTSR increase in cytokine release syndrome (CRS) after a Phase II trial completion, jumping by nine points to 60%.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access